Core Viewpoint - The board of directors of Mayinglong Pharmaceutical Group Co., Ltd. approved the 2025 semi-annual report and the remuneration plans for directors and senior management during the 21st meeting of the 11th board session held on August 27, 2025 [1][2]. Group 1: 2025 Semi-Annual Report - The 2025 semi-annual report was approved with unanimous support from the board members, indicating a strong consensus on the report's content [1]. Group 2: Remuneration Plans - The independent directors will receive a fixed annual allowance of 180,000 yuan (including tax), paid monthly [2]. - Non-independent directors not involved in daily management will receive a fixed annual allowance of 120,000 yuan (including tax), also paid monthly [2]. - The remuneration for non-independent directors and senior management involved in daily operations will consist of a basic salary and performance-based pay, determined by their roles and the company's annual performance assessment [2].

Group 1 - The company held its fifth extraordinary shareholders' meeting in 2025, resulting in the election of the 11th board of directors [1] - The first meeting of the 11th board was conducted on June 19, 2025, with a combination of in-person and communication methods [1] - Mr. Weng Zhanbin was elected as the chairman of the 11th board, with a unanimous vote of 7 in favor [1] Group 2 - The company established specialized committees within the board, including the Strategic Development Committee, Nomination Committee, Compensation Committee, Audit Committee, and Risk Control Committee, with specific members appointed [2] - Mr. Tang Lei was appointed as the general manager of the company, also with a unanimous vote of 7 in favor [2] - Mr. Sun Yingxiang and Mr. Sun Tieming were appointed as deputy general managers, and Ms. Yang Limin was appointed as the financial director, all with unanimous approval [3] Group 3 - Ms. He Ming was appointed as the securities affairs representative, with a unanimous vote of 7 in favor [5] - The company proposed a compensation scheme for directors and senior management, which was reviewed and approved by the compensation committee [6] - The company plans to adjust and add daily related transactions based on the original expected transactions, with the proposal requiring shareholder approval [6]

Core Viewpoint - The company has approved the compensation plans for the fourth board of directors and senior management, linking their remuneration to the company's performance and market standards [1][2]. Summary by Sections Compensation Plan for Board of Directors - The compensation plan applies to all members of the fourth board of directors, including independent and non-independent directors, as well as employee representative directors [1]. - The plan is set for the duration of their term [2]. - Internal directors' compensation is tied to the company's annual performance and consists of basic salary, performance salary, and other benefits [2]. - External directors receive a fixed allowance of 78,000 yuan per year, with no additional compensation or social security benefits [2]. - Independent directors receive a fixed allowance of 100,000 yuan per year, with no additional compensation or social security benefits [2]. Compensation Plan for Senior Management - The compensation plan for senior management is also linked to the company's performance and includes basic salary, performance salary, and other benefits [2]. - Basic salary is determined based on the position's value, responsibility, capability, and market salary trends [2]. - Performance salary is based on the annual performance evaluation scheme for senior management [2]. - Other benefits include social insurance and housing provident fund contributions as per national and local regulations [2].